Vandenplas, Yannick
Simoens, Steven
Van Wilder, Philippe
Vulto, Arnold G.
Turk, Florian
Huys, Isabelle
Article History
Received: 15 June 2022
Accepted: 21 September 2022
First Online: 29 September 2022
Declarations
:
: The authors confirm that all experiments were performed in accordance with relevant guidelines and regulations (including the Declaration of Helsinki). This study was approved by the Ethics Committee Research of UZ/KU Leuven (S65328). Written informed consent was obtained from all participants prior to the study.
: Not applicable.
: This research project is funded by the Belgian National Institute for Health and Disability Insurance (NIHDI). NIHDI was not involved in the design of the study and collection, analysis, interpretation of data, nor in writing the manuscript.SS, IH and AGV founded the KU Leuven Fund for Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). SS was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer, and MSD; he has participated in advisory board meetings for Pfizer, Sandoz, and Amgen; he has contributed to studies on biologics and biosimilars for Hospira (together with AGV and IH), Celltrion, Mundipharma, and Pfizer; and he has had speaking engagements for Amgen, Celltrion, and Sandoz. AGV is involved in consulting, advisory work, and speaking engagements for several companies, including AbbVie, Accord, Amgen, Biogen, EGA, Effik Benelux, Pfizer/Hospira, Mundipharma, Roche, and Sandoz. PVW acted as a healthcare consultant to public and private organizations, including pharmaceutical companies and their professional associations. FT acts as an advisor to, and is a consultant for, several pharmaceutical organizations and has represented pharmaceutical organizations in professional associations.All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.